SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPath is drawing attention after securing an order for more than 50,000 optical assemblies for drone cameras from an unnamed defense customer. Traders view it as a sign of counter-drone demand, though speculation that the customer is Leonardo DRS remains unconfirmed, and some investors remain cautious amid share-price weakness and upcoming earnings.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,546,266,383.70521. The last known price of Dogecoin is 0.07588453 USD and is up 0.89 over the last 24 hours. It is currently trading on 1543 active market(s) with $1,129,852,058.92 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoins choppy trading around the eight-cent area, including repeated slips below that level alongside weakness in other crypto and meme coins, dominates the discussion. Traders are split between expecting further downside and buying the dips or holding for a recovery, with no clear DOGE-specific catalyst emerging.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

Traders are focused on Middle East LNG supply disruptions, including reported damage to Qatars export infrastructure and risks around the Strait of Hormuz, which they see as a potential long-term tailwind for U.S. LNG exporters such as NextDecade. The bullish view is tempered by concerns that Rio Grande LNG is still under construction and NEXT may not produce LNG until 2027, leaving execution, financing, and timing risks before it can benefit directly.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Discussion centers on Zebecs payroll and payments expansion, particularly its MoneyGram/Stellar connection and reported European and Robinhood Chain integrations, which bullish traders see as signs of growing adoption. Others argue that partnerships and reported business metrics have yet to translate into stronger, sustained demand for ZBCN, and complain that the tokens price remains weak.

Basic Attention Token (BAT) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Basic Attention Token has a current supply of 1,500,000,000 with 1,495,724,656.95260575 in circulation. The last known price of Basic Attention Token is 0.13064027 USD and is up 2.94 over the last 24 hours. It is currently trading on 591 active market(s) with $15,372,551.09 traded over the last 24 hours. More information can be found at https://basicattentiontoken.org/.

Basic Attention Token

BAT is drawing attention after a sharp rally alongside strength in other altcoins, with traders focused on whether technical momentum can sustain a breakout. Some see healthy consolidation and another leg higher, while others expect profit-taking or a pullback; no specific token catalyst is clearly confirmed.

Amp (AMP) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Amp has a current supply of 99,720,267,351.28921674 with 89,781,193,103.18022 in circulation. The last known price of Amp is 0.0006528 USD and is up 0.85 over the last 24 hours. It is currently trading on 193 active market(s) with $5,174,420.89 traded over the last 24 hours. More information can be found at https://amp.xyz.

AMP Token

AMP is drawing attention after a sharp rally and volume surge, with traders noting its strength amid broader crypto weakness and debating whether the move can hold or will fade like previous pumps. Some bullish posts point to Flexa payments and Anvil collateral infrastructure as longer-term potential, but no single confirmed announcement is driving the discussion.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on volatile Dow moves and its relative performance versus the Nasdaq and S&P, with traders split between crash warnings and bullish dip-buying. Fed and interest-rate concerns, rising yields, and oil-related geopolitical risks recur as market explanations, but no single catalyst dominates.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention after a breakout to a fresh 52-week high, with traders pointing to call-heavy options activity, short-covering potential and anticipation of Q3 results. Buyout speculationparticularly around Sanofiis prominent, but others see the move as pre-earnings positioning tied to BRIUMVIs growth and stress that no deal has been confirmed.

Cosmos (ATOM) is a cryptocurrency . Cosmos has a current supply of 538,743,080.257876. The last known price of Cosmos is 1.54934617 USD and is up 3.36 over the last 24 hours. It is currently trading on 999 active market(s) with $34,414,170.84 traded over the last 24 hours. More information can be found at https://cosmos.network/.

Cosmos

Cosmos ATOM is drawing attention amid persistent price weakness, with holders highlighting staking rewards and hoping for renewed adoption and an altcoin rebound. Bearish traders counter that token inflation and a fading ecosystem are weighing on the outlook; institutional-adoption and regulatory catalysts remain largely speculative in the discussion.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention as the equal-weight S&P 500 has outperformed cap-weighted indexes amid weakness in mega-cap tech, with traders viewing the move as a rotation and broader market participation. Some see the strength and recent highs as a healthier rally, while others question whether breadth can hold or warn that the divergence may signal trouble.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Novartis (NVS) Rating Upgrade to Buy

Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns

Alnylam's shares fall 25% despite Q3 beat as slower Amvuttra patient starts and demand concerns weigh on investor sentiment.

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?

Here is how Avantor, Inc. (AVTR) and Novartis (NVS) have performed compared to their sector so far this year.

A pharma giant is moving past one patent cliff  but another is already looming

Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks...

INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised

Incyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.

How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3?

Eli Lilly is expanding beyond GLP-1 drugs as neuroscience and immunology therapies fuel growth ahead of Q3 results, with Kisunla, Taltz and newer drugs in focus.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie

Eli Lilly, Novartis, Johnson & Johnson and AbbVie advance arthritis treatment portfolios through strong drug sales, clinical progress and regulatory expansions.

4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential

LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis AG - ADR

Novartis Discontinues Mid-Stage Lupus Trial In Latest Pipeline Setback 

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Iptacopan is sold under the brand name Fabhalta and is approved by the FDA for Paroxysmal Nocturnal Hemoglobinuria, Primary Immunoglobulin A Nephropathy, and C3 Glomerulopathy.</li><li>Novartis has faced multiple clinical setbacks over the past several weeks, including trial failures and development discontinuations.</li><li>According to data from Koyfin, 8 of the 23 analysts rate the stock a ‘buy’ or ‘strong buy,’ while 13 rate it a ‘hold’ and only two rate it ‘sell.’</li></ul> Shares of Novartis (NVS) closed little changed on Friday after the company decided to discontinue its mid-stage trial of iptacopan in lupus nephritis.According to a federal clinical trials registry update, the company has concluded the study over ‘strategic considerations.’ It is unclear if the discontinuation was spurred by efficacy or safety concerns.The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment. The company decided to conclude the study after completing the first part, as per the database.Iptacopan is sold under the brand name Fabhalta and is approved by the FDA for Paroxysmal Nocturnal Hemoglobinuria, Primary Immunoglobulin A Nephropathy, and C3 Glomerulopathy.<h2 class="st-heading-2">Latest Pipeline Setback For Novartis</h2>Novartis has faced multiple clinical setbacks over the past several weeks. Last month, the company said that its late-stage trial of Pelacarsen, being developed as a treatment to lower elevated lipoprotein(a) or Lp(a) and reduce the risk of major cardiovascular events, missed its primary goal. The company also said that its late-stage trial of del-desiran in myotonic dystrophy type 1 (DM1) missed its primary endpoint.Besides the late-stage drug failures, the company also discontinued development of VHB937 in mid-September after a mid-stage study missed primary and secondary goals. &nbsp;Prior to that, in August, Novartis paused multiple autoimmune and neurology trials after three fatal cases of immune effector cell-associated hemophagocytic syndrome (IEC-HS) in patients taking its experimental therapy Rap-cel. &nbsp;According to data from Koyfin, 8 of the 23 analysts rate the stock a ‘buy’ or ‘strong buy,’ while 13 rate it a ‘hold’ and only two rate it ‘sell.’<h2 class="st-heading-2">How Did NVS Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$NVS" data-symbol-id="NVS" href="https://stocktwits.com/symbol/NVS" target="_blank">NVS stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.NVS stock has gained 9% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/asnd-shares-shrug-off-positive-european-opinion-for-fda-approved-achondroplasia-drug/cZxKWRBRBtT">ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment in lupus. 

Novartis Discontinues Mid-Stage Lupus Trial In Latest Pipeline Setback

The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment in lupus. 


Dimensional ETF Trust - Dimensional International Core Equity Market ETF

Dimensional International Value ETF

Novartis AG

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$2.24	--	--	N/A
Q3 '26	$2.27	$2.46	8.32%	BEAT
Q2 '26	$2.17	$2.41	10.95%	BEAT
Q1 '26	$2.10	$1.99	-5.13%	MISSED
Q4 '25	$1.98	$2.03	2.38%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

NVS Earnings

Latest Earnings Results: Q3 '26

Historical Earnings